FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data
22nd September 2025 Uncategorised 0The FDA has issued a complete response letter to Lundbeck and Otsuka, scuppering their ambition to launch the atypical antipsychotic Rexulti—in combination with Viatris’ Zoloft—as a novel treatment for post-traumatic stress disorder.
More: FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data
Source: fierce